CHEMCON

12th November 2022 To, To, BSE Limited National Stock Exchange of India Limited Listing Compliance & Legal Regulatory Listing & Compliance Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Mumbai - 400 001 Bandra East, Mumbai 400 051 Stock Code: 543233 Stock Symbol: CHEMCON Dear Sir/Madam, Sub: Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclose herewith the “Investor Presentation” for November, 2022. The aforementioned presentation has been uploaded on the company’s website www.cscpl.com. We request you to take the above on your records. Thanking you, Yours faithfully, For Chemcon Speciality Chemicals Limited ____________________ Shahilkumar Kapatel Company Secretary & Compliance Officer Membership No.: A52211 Chemcon Speciality Chemicals Limited Investor Presentation –November 2022 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Chemcon Speciality Chemicals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offeringdocument containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of,or any omissionfrom,this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forwardlooking statements made fromtime to time by or on behalf of the Company. 2 Business Highlights “Q2FY23 Business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers. Most of our clients are facing challenges due to adverse pricing scenario across formulation & softening of demand. For Q2FY23, we have registered a revenue of Rs 58 crores for the quarter as both HMDS & CMIC has underperformed in the domestic market. On the other hand, robust performance in the export market has partly negated the subdued performance. Also, inorganic bromides have been affected marginally due to inconsistent sourcing of key raw material bromine. As a part of diversification strategy and business expansion, we have successfully commenced the commercial production of Bromo Benzene at P9 facility which will cater to Agrochemical manufacturers in the global market. With the expansion of Bromo Benzene, we will be adding Organic Bromides in our product basket. We are awaiting necessary approvals from regulatory authorities for another pharma chemical, Guanine at P9 Unit. We will be adding few other chemicals which are imported in India at P10 Unit and expect to commence production by Q1FY24. Recently, we have purchased a land parcel at Gothda, near Vadodara for future leg of expansion and invested in solar power plant for captive purpose which will reduceourpowercost. Over the years, we have invested in the company to improve the product basket and add meaningful capacities. The company is also looking to establish vast presence in export market with diversified product mix. India imports many pharmaceutical chemicals, which offers a plenty of space fora producerlike us tobecomea long-termtrustworthy and sustainable domesticpartner.” Mr. KamalAggarwal, Chairman& ManagingDirector 4 Performance Highlights Total Revenue (Rs. Cr) EBITDA (Rs. Cr) PAT (Rs. Cr) 89.4 33.6 25.5 61.2 57.9 18.9 14.6 9.6 7.8 Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Geographic-Wise (%) Business-wise (%) Production Volume (MT) 2,051 1% 1% 1% Others Export 43% 47% Oilwell 37% 31% 28% 1,420 1,035 1,352 71% Oilwell 584 729 Domestic 57% 53% Ch P e h m a i r c m al a s 62% 68% 71% HMDS 447 512 472 29% CMIC 389 504 151 Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q1 FY23 Q2 FY23 Export data are inclusive of Deemed Exports 5 Financial Trends Total Revenue (Rs. Cr) EBITDA (Rs. Cr) PAT (Rs. Cr) 147.3 43.1 33.3 36.8 28.0 118.4 H1FY22 H1 FY23 H1FY22 H1FY23 H1 FY22 H1FY23 Geographic-Wise (%) Business-wise (%) Production Volume (MT) 3,403 0% 1% Others 2,849 Export 37% 24% 30% 56% Oilwell Oilwell 1,048 1,764 Domestic 63% Speciality 76% 69% HMDS 1,039 984 44% CMIC 762 655 H1FY22 H1FY23 H1FY22 H1 FY23 H1FY22 H1FY23 Export data are inclusive of Deemed Exports 6 Recent Developments Recent Developments Commissioning of Solar Power Plant Land Acquisition » Commissioned ~2.1 MW solar » Purchased a land parcel at powerplantatDabhoi,Vadodara Gothda, near Vadodara for future legofexpansion Commercialization P10 unit by Q1FY24 Commercialization P9 unit » It will be used for captive purpose » New range of pharma chemicals will whichwillreduceourenergycost » Commenced commercial production of P9 beadded facilityatManjusar » Capacity addition of 2,400 MTPA of Bromo Benzene » Awaiting necessary approval from regulatory authorities to add a new pharmachemical,Guanineatsameunit 7 Profit & Loss Statement Particulars (Rs. Crs) Q2 FY23 Q2 FY22 Y-o-Y H1FY23 H1FY22 Y-o-Y Revenuefrom Operations 57.9 61.2 -5.4% 147.3 118.4 24.4% Cost of Goods Sold 35.0 30.8 73.2 59.5 Employee Cost 4.9 4.8 10.6 9.0 Other Expenses 8.4 6.7 20.4 13.1 EBITDA 9.6 18.9 -49.4% 43.1 36.8 17.2% EBITDA Margin 16.6% 30.9% 29.3% 31.1% Other Income 3.3 2.3 6.0 4.2 Depreciation 2.1 1.5 4.0 3.0 EBIT 10.8 19.7 45.1 38.0 Finance Cost 0.2 0.2 0.4 0.4 Profit before Tax 10.6 19.5 44.7 37.6 Tax 2.8 5.0 11.4 9.6 PAT 7.8 14.6 -46.3% 33.3 28.0 18.9% PAT Margin % 13.5% 23.8% 22.6% 23.6% Basic EPS 2.14 3.98 9.09 7.64 8 Balance Sheet ASSETS (Rs. Crs) Sep-22 Mar-22 EQUITY AND LIABILITIES Sep-22 Mar-22 EQUITY AND LIABILITIES Non-Current Assets Equity a) Property, Plant And Equipment 92.2 81.7 a) Equity Share Capital 36.6 36.6 b) Capital Work in Progress 37.1 34.0 b) Other Equity 399.1 380.6 c) Right Of Use Asset 0.2 0.5 Total Equity 435.7 417.2 d) Intangible Assets 0.0 0.0 Liabilities e) Other Financial Assets 0.9 0.9 Non-Current Liabilities a) Financial Liabilities f) Other Non-Current Assets 12.3 5.1 i) Borrowings 0.9 0.6 ii) Lease Liabilities 0.0 0.2 Sub-Total -Non-Current Assets 142.6 122.3 iii) Other Financial Liabilities 1.4 2.1 b) Non current Provisions 0.1 0.1 Current Assets c) Deferred Tax Liabilities (Net) 1.1 0.3 Sub-Total -Non-Current Liabilities 3.5 3.2 a) Inventories 70.9 34.6 Current Liabilities b) Financial Assets a) Financial Liabilities i)Trade Receivables 80.7 102.5 i) Borrowing 36.5 34.9 ii) Cash And Cash Equivalents 22.0 35.9 ii) Trade Payables 17.8 23.9 iii) Bank Balances 172.5 188.2 iii) Other Financial Liabilities 8.6 7.1 iv) Other Financial Assets 7.8 5.5 iv) Lease Liabilities 0.2 0.3 b) Other Current Liabilities 1.3 9.8 c) Other Current tax Assets 0.0 0.7 c) Short Term Provisions 0.0 0.0 d) Other Current assets 10.8 8.3 d) Current tax liabilities 3.6 1.5 Sub-Total -Current Assets 364.7 375.7 Sub-Total -Current Liabilities 68.1 77.6 Total -Assets 507.3 498.0 Total -Equity And Liabilities 507.3 498.0 9 Cash Flow Statement Particulars (Rs. Crs.) Sep-22 Sep-21 Net Profit Before Tax 44.7 37.6 Adjustments for: Non Cash Items / Other Investment or Financial Items -0.8 -0.6 Operating profit before working capital changes 43.9 37.0 Changes in working capital -32.2 15.8 Cash generated from Operations 11.8 52.8 Direct taxes paid (net of refund) 7.8 11.3 Net Cash from Operating Activities 4.0 41.5 Net Cash from Investing Activities -4.5 -57.4 Net Cash from Financing Activities -13.3 59.7 Net Decrease in Cash and Cash equivalents -13.9 43.8 Add: Cash & Cash equivalents at the beginning of the period 35.9 24.4 Cash & Cash equivalents at the end of the period 22.0 68.1 10 Company Snapshot Incorporated in 1988 Only Manufacturer of HMDS in India Manufacturer of Speciality Chemicals 3rd Largest Manufacturer of HMDS Worldwide An ISO 9001:2015 and ISO 14001:2015 Certified Company Largest Manufacturer of CMIC worldwide BusinessVerticals: Pharmaceuticals & Oilwell Completion Chemicals Only Manufacturer of Zinc Bromide in India Manufacturing Facilities near Manjusar, Vadodara, Gujarat LargestManufacturer of Calcium 9Operational Plants, 6 Owned and 2 Bromide in India lease Warehouses 12 Evolution FY89 FY95-98 FY01-03 FY05 FY14 FY15-16 » Company was » First sale of few » Commenced HMDS » First export shipment of » First sale of CMIC » First sale ofCalcium incorporated as chemical products Business in 2001 HMDS Bromide(Solution) Gujarat Quinone • Pyridine Private Limited Hydrobromide » Discontinued few » Amalgamation of Chemcon » First sale of Zinc • Para Nitro Benzyl products due to Engineers Private Limited Bromide(Solution Bromide lower demand with Gujarat Quinone • Methyl Iodide Private Limited; name • GA-1 changed to “Chemcon SpecialityChemicals Private Limited” FY17 FY18 FY19 FY20 FY21 FY22 » Plant P2 commissioned » First sale of Calcium » Increase in annual » Increase in HMDS » Increase in CMIC & » Increase in annual with a capacity to Bromide(Powder) installed production Capacity by TMCS Capacity by installed production manufacture upto600 capacity for commissioning of plant commissioning of plant capacity for CMIC MTPA of Hi-Purity HMDS » First sale of Sodium • CMICfrom 600 to P7 P8 from 1,200 MTPA to » Product development of BromideSolution 1,200 MTPA; 1,800 MTPA New Chemicals 4 CBC • Oilwell Completion and 2,5DHT completed Chemicals from 7,200 » Commercial supplies of to 14,400 MTPA 4CBC started 13 Global Market Presence Global Presence Key Countries » United States of » Japan America » United Arab FY22 Export Contribution*: » Italy Emirates ~37% » South Korea » Russia » Germany » Spain » People’s Republic of » Thailand China » Malaysia Over Two Decades of • Manufacturing Well Equipped to Seize Upcoming Opportunities Experience in Chemicals • Exports *Export data are inclusive of Deemed Exports 14 Entry Barriers Complex Chemistry Stringent Impurity Measure » The involvement of complex chemistry in » Our processes and products are subject to, and the manufacture of the Products, which is measured against, high quality standards and difficult to commercialize on a large scale stringent impurity specifications Long Gestation Period Technical Know-how Entry Barriers » Handling chemicals requires a high degree of technical » Customer acquisition involves a long gestation skill and expertise and operations involving such period, resulting in a very few players being hazardous chemicals ought to be undertaken only by involved in manufacturing of the products personnel who are well trained to handle such chemicals Regulatory Norms High Replacement Cost » Any change in the vendor of the product » To comply with all regulatory norms and may require significant time and cost for the filings with various agencies customer 15 Key Long-Term Relationships Pharmaceutical Chemicals Oilwell Completion Chemicals Inorganic HMDS CMIC Bromides Shree Radha CC Gran Limited Overseas Liability Company Longstanding New Product New Customer Strong Base Clients Development Reach Top 7 customers Leading to increase Fewcustomers age Well equipped to Top 5 customers Top 10 customers have been with us in new product more than 2 retain market contribute < 50% contribute < 65% for more than 4 base and reach out decades with us presence years to new customers The Brand Names mentioned are the property of their respective owners and are used here for identification purpose only 16 Moving up the Value Chain Added New Product like FY15 Revenue FY22 Revenue Business 4 CBC, 2,5 DHT & BromoBenzeneOthers Rs 64 Crs Rs 257 Crs Commenced CMICbusiness in2014 CMIC Rs 10 Crs Rs 68 Crs Commenced HMDS business in 2001 HMDS Rs 36 Crs Rs 122 Crs Bromides Rs 13 Crs Rs 60 Crs Commenced Bromide business in 2015 Others Rs 5 Crs Rs 7 Crs 17 Board of Directors : Experienced Team Kamalkumar Rajendra Aggarwal Navdeep Naresh Goyal Chairman and Managing Director Deputy Managing Director » Holds Diploma in Petrochemical Technology (Plastic » He has more than 11 years of experience in operations. He Technology) from the Maharaja Sayajirao University of has been on the Board since April 1, 2015. Baroda, Gujarat » He is actively involved in the decision making and » He has more than 26 years of experience in the specialized management of day-to-day operations. chemicals industry. He has been on our Board since January 19, 2004 Rajesh Chimanlal Gandhi Himanshu Purohit Whole-time Director and Chief Financial Officer Whole-time Director » Holds a Bachelor’s Degree in Commerce from Gujarat » He holds a Master’s Degree in Science in Inorganic Chemistry University from the Sardar Patel University, Gujarat » He has more than 23 years of experience in finance & » He has more than 23 years of experience in production related accounts and related operations. He has been on our Board operations. He has been on our Board since May 1, 2012 since May 1, 2012 Rajveer Aggarwal Whole-time Director » He holds a bachelor’s degree in chemical engineering from the Gujarat Technological University, Gujarat » He has more than six years of experience in operations. He has been on the Board since Oct 2017 18 Board of Directors : Independent Directors Lalit Chaudhary Pradeep Agarwal Independent Director Independent Director » Qualified as Chartered Accountant and Company Secretary » He holds a bachelors’ degree in commerce from the Sardar » He is also an Independent Director of Bharat Petroleum Corporation Patel University, Gujarat Limited as a director since 1993. Limited and alsoengaged in social activities » He has more than 21 years of experience as an entrepreneur. » He has more than 25 years of experience. He also acts as a Trustee He has been on the Board since April 29, 2019 of the various Trusts Bharat Shah Neelu Shah Independent Director Independent Director » He holds a bachelor’s degree in science from the Maharaja » She holds a bachelor’s degree in science from Kanpur University, UP Sayajirao University of Baroda, Gujarat. and an MBA from the JiwajiUniversity, Gwalior » In the past, he has been associated with Bank of Baroda in » She has 6 years of experience in sales and has been on the Board various roles since April 29, 2019 » He has more than 38 years of experience in the financial services sector. He has been on the Board since April 29, 2019 Samir Chandrakant Patel Independent Director » He holds a master’s degree in science from the Sardar Patel University, Gujarat. » He has more than 31 years of experience. He has been on the Board since April 29, 2019 19 Key Certifications Key Certificates R&D Environment In-house laboratory to test Complying All Environment Laws » Raw materials procured » The Environment (Protection) Act, 1986 » New Products & Innovation » Water Prevention and Control of Pollution Act » Final products testing at the various stages of the » Air Prevention and Control of Pollution Act, 1981 manufacturing process » We are a zero-discharge company » Well equipped with new instruments & machinery 20 Market Overview Oilwell Completion HMDS CMIC Chemicals Global Market ~35,700 MT ~6,880 MT ~362,000 MT Capacity (CY19) Global Market ~25,390 MT ~3,927 MT ~246,000 MT Production (CY19) ChemconProduction 2,068 MT 1,295 MT 2,703 MT (FY22) ChemconShare in > 5% > 30% ~1% Global Market Domestic Import ~1,622 MT ~1,574 MT - (CY19) We are well positioned to substitute imports and maintain growth trajectory Source: Frost & Sullivan 22 HMDS Hexamethyldisilazane / Hexamethyldisilane » HMDS, an organosilicon compound, is a reagent and a precursor to bases that are popular in organic synthesis and organometallic chemistry » HMDS is widely used in the pharmaceutical industry as a silylatingagent in the process of manufacture of pharmaceutical drugs of the Penicillin group and may also be used in the semiconductor electronics industry and in vinyl silicone rubber to improve their tearing strength Key Attributes* End Applications » Pharmaceutical: As a silylatingagent in the process of manufacture of pharmaceutical drugs of the Penicillin group Only Manufacturer in 3rd Largest Manufacturer » Semiconductor: Surface treatment agent of diatomite, white carbon black, titanium and India Worldwide blond additives of photoresist » Organic Synthesis: Precursor to many bases common in organic synthesis and organometallic chemistry » Others: Photolithography, electron microscopy and pyrolysisgaschromatography-mass spectrometry Capacity Business Performance (Rs in Cr) % of Total 41% 43% 50% 50% 47% Revenue Product Period Capacity Production Utilisation 130 131 121 122 23 17 19 26 HMDS FY22 4,200 2,068^ 49% 65 Export 11 108 115 102 95 Hi-Purity HMDS FY22 600 - Domestic 54 ^Includes Outsource Capacity FY18 FY19 FY20 FY21 FY22 Source: Frost & Sullivan *Above data are as per CY19 Export data are inclusive of Deemed Exports 23 CMIC Chloromethyl Isopropyl Carbonate » CMIC (chloromethyl isopropyl carbonate) is an antiviral drug intermediate product, which is a key intermediate for anti-AIDS andanti-hepatitis B drug Tenofovir » The downstream product of chloromethyl isopropyl carbonate, Tenofovir is a nucleotide antiviral drug developed by Gilead Corporation of the United States. Tenofovir and its combination preparations have become the largest sales of anti-AIDS drugs Key Attributes* End Applications » CMIC is mainly used in pharmaceutical industry as a key intermediate for anti- Largest Manufacturer AIDS anti-hepatitis B drug Tenofovir Worldwide » CMIC can also be used in synthesis of other antiviral drugs Capacity Business Performance (Rs in Cr) % of Total 21% 16% 13% 35% 26% Revenue Product Period Capacity^ Production Utilisation 84 68 40 CMIC FY22 1,800 1,295 ~72% 48 32 33 34 Export 25 10 ^Exclude recently added capacity of 1,200 MT 18 44 36 Domestic 14 23 24 FY18 FY19 FY20 FY21 FY22 Source: Frost & Sullivan *Above data are as per CY19 Export data are inclusive of Deemed Exports 24 Oilwell Completion Chemicals Inorganic Bromides: Calcium Bromide, Zinc Bromide and Sodium Bromide » Oilwell Completion Chemicals are used to complete the well and is normally a salty solution made up of chlorides or bromides » In addition to cleaning the wellbore, after the drilling is finished, completion chemical is used to control the pressure down-hole, prior to and while well completion operations are in progress » We manufacture a range of inorganic bromides, namely: Calcium Bromide (solution and powder), Zinc Bromide (solution) & Sodium Bromide (solution and powder) Key Attributes* End Applications » Sodium Bromide (NaBr) : Used alone or in a combination with sodium chloride or zinc bromide to form clear workaround and drilling fluids; useful when used in Only Manufacturer of Largest Manufacturer of formations that are known to have sensitivity towards calcium Zinc Bromide in India Calcium Bromide in India » Zinc Bromide (ZnBr2): Clear, solid-free brine fluid; it can be used with other bromides and chlorides to prepare non-damaging liquids » Calcium Bromide (CaBr2): Used as a completion and work-over fluid to control wellbore pressures in upstream oil & gas operations Capacity Business Performance (Rs in Cr) % of Total 36% 35% 33% 13% 23% Revenue Product Period Capacity Production Utilisation 107 88 Bromides 49 FY22 15,000 2,703 ~18% 56 60 (Total) Export 78 31 37 46 58 10 Domestic 11 10 21 23 FY18 FY19 FY20 FY21 FY22 Source: Frost & Sullivan *Above data are as per CY19 Export data are inclusive of Deemed Exports 25 Manufacturing Facilities » P4 » P7 » P6 » P5 » P8 » P9 » P10 » P1 » P3 » P2 Improving Dedicated Plants Multipurpose Plants In-house Laboratory Warehouses Efficiencies 26 Manufacturing Facilities Installed Capacity Volume Reactor Located at Manjusarnear Plant No Product categories Product Manufactured (MT P.A) Capacity (In KL) Vadodara, Gujarat P-3 & P-7 HMDS and ancillary products 4,200 177.80 9Operational Plants P-2 HMDS (hi-purity) 600 13.00 P-4 CMIC 1Proposed Expansion Plant 3,200 121.75 under process Pharmaceutical P-6 Multipurpose Capacity -CMIC, 4 CBC & 2,5 DHT Chemicals P-8 Multipurpose Capacity -TMCS, CMIC 3,600 In-House R&D Laboratory P-9 Bromo Benzene 2,400 Proposed Multipurpose Capacity P-10 Q1FY24e - 6 Owned + 2 Lease Warehouses (Pharma Intermediate Chemicals) Calcium Bromide (solution), Zinc Bromide (solution) and P-5 14,400 57.30 Sodium Bromide (solution) Oilwell Completion 2 Marketing Offices in Chemicals P-1 Calcium Bromide (powder) 600 5.00 Mohali & Hyderabad » eHMDS(also known as hi purity HMDS) capacity can be used for HMDS Total Capacity (MTPA) 29,000 374.85 » CMIC capacity can be used for HMDS purpose » P7 has the flexibility to manufacture 4 CBC & 2,5 DHT products 27 Growth Drivers Capacity Expansion Import Substitution » We intend to build two additional plants P9 & P10 unit in FY23 » India’s current domestic demand is being catered by imports for HMDS and CMIC » These additional plants will manufacture chemicals which are principally used in the » We are the only manufacturer of HMDS in India and the largest manufacturer of pharmaceutical industry CMIC in India in terms of production in the calendar year 2019, aims to capitalize on the potential growth in the demand for CMIC and HMDS in India and to substitute imports Exploring NewApplications Cost Efficiencies » Aim to expand the sale of our products to other industries where our products have » We intend to continue to be cost-efficient in the production of our products. This an application efficiency is achieved through strategies like – » For instance, for HMDS, we aim to market our products for end-use applications in • Having a large single-location manufacturing facility other industries including the rubber and semiconductor manufacturing industry • Dedicated plants for each product • Process re-engineering for efficient raw material consumption » Company has recently commissioned a new plant specifically to produce high purity • Being a sizeable player in the industry in each of our products HMDS which finds usage in semiconductor industry 28 Way Forward Exploring Moderate Growth in Moderate Recovery in Opportunities in Pharma Industry Oil Industry New Products Leading to Long Term Sustainable Growth New Products, New Clients, New Applications, New Opportunities 29 Financial Trends Total Revenue (Rs. Cr) EBITDA (Rs. Cr) PAT (Rs. Cr) +13.0% +16.0% +24.2% 303.3 81.1 81.6 62.8 262.1 257.1 70.3 56.4 243.5 66.1 48.9 43.0 157.6 45.1 26.4 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Geographic-Wise (%) Business-wise (%) Production Volume (MT) 11,118 Others 2% 6% 3% 13% 0% 1% 9,762 Export 48% 32% 40% 29% 37% Oilwell 36% 35% 34% 23% 8,511 6,840 8,248 6,039 6,065 Oilwell 5,847 2,011 Domestic 52% 68% 60% 71% 63% Ch P e h m a i r c m al a s 62% 59% 63% 87% 76% HMDS 1,588 1,674 2,915 3,033 2 2 , , 0 7 6 0 8 3 CMIC 1,076 1,196 808 1,796 1,295 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Export data are inclusive of Deemed Exports 31 Performance Highlights Total Revenue (Rs. Cr) 130 131 121 122 107 84 88 65 68 60 56 48 33 34 31 HMDS CMIC Oilwell FY18 FY19 FY20 FY21 FY22 Production Volume (MTPA) 8,248 5,847 6,039 2,915 3,033 2,703 1,588 1,674 2,068 1,796 2,011 1,076 1,196 1,295 808 HMDS CMIC Oilwell 32 Key Ratios Fixed Asset Net Debt/ equity (x) Turnover(x) 0.35 7.7 0.32 0.31 5.3 5.5 3.7 3.2 0.09 0.01 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 ROCE (%) ROE (%) 61% 49% 45% 49% 34% 35% 21% 19% 16% 15% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 33 Utilisation of the Net IPO Proceeds Original Cost Utilisation Upto UnutilisationAmounts Particulars Revised Cost (as per Prospectus) 30-09-2022 as on 30-09-2022 Capital expenditure towards expansion of Manufacturing Facility 41.0 41.0 41.0 - Incremental working capital requirement 90.0 90.0 90.0 - General corporate purposes* 18.8 19.3 19.3 - Total 149.8 150.3 150.3 - *The revision in generalcorporate purposes expense is on account of reduction in offer expense as compared to estimated. 34 Thank You ChemconSpecialityChemicals Ltd. CIN –L24231GJ1988PLC011652 Mr. Rajesh Gandhi -CFO Email –rajesh@cscpl.com www.cscpl.com Strategic Growth Advisors Pvt. Ltd. CIN -U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Pankti Majithia Email -shrikant.sangani@sgapl.net/ pankti.majithia@sgapl.net +91 9619595686 /91+ 9619611096 www.sgapl.net